Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Next Previous
Trial Profile

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anamorelin (Primary)
  • Indications Anorexia; Cachexia
  • Focus Registrational; Therapeutic Use
  • Acronyms ROMANA-1
  • Sponsors Helsinn Therapeutics

    • Most Recent Events

    • 12 Sep 2017 Results (n=829) of pooled post hoc analysis of NCT01387269 and NCT01387282 assessing the baseline characteristics of patients with mGPS 0-2 presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results (n=829) of pooled post hoc analysis of NCT01387269 and NCT01387282 trials assessing efficacy of anamorelin in cachectic non small cell lung cancer patients with modified Glasgow Prognostic Score 2 (C-reactive protein levels more than 10mg/L and albumin levels less than 3.5g/dL) presented at the 42nd European Society for Medical Oncology Congress
    • 02 Jun 2017 Results of post-hoc pooled analysis (n=829) of two pivotal trials (ROMANA 1 and ROMANA 2) assessing the body weight response with anamorelin, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top